A Randomized Phase II Study Of Carboplatin And Etoposide With Or Without G3139 (NSC #683428, IND #58842) In Patients With Extensive Stage Small Cell Lung Cancer.
Phase of Trial: Phase II
Latest Information Update: 11 Jan 2013
At a glance
- Drugs Oblimersen (Primary) ; Carboplatin; Etoposide
- Indications Small cell lung cancer
- Focus Therapeutic Use
- 13 May 2008 The expected completion date for this trial is now 1 Feb 2008.
- 11 May 2008 Status changed from in progress to completed, as reported by ClinicalTrials.gov.
- 20 Feb 2008 Results have been presented.